

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A method of extending survival and/or delaying disease progression by treating a human ovarian or breast tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to ~~a monoclonal antibody or antigen-binding fragment thereof which has the identifying characteristics of a~~ the isolated monoclonal antibody ~~encoded by a clone produced by the hybridoma~~ deposited with the ATCC as accession number PTA-5643 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and/or survival is extended.

Claim 2. (Original) The method of claim 1 wherein said antibody is conjugated to a cytotoxic moiety.

Claim 3. (Original) The method of claim 2 wherein said cytotoxic moiety is a radioactive isotope.

Claim 4. (Withdrawn) The method of claim 1 wherein said antibody activates complement.

Claim 5. (Currently amended) The method of claim 1 wherein said antibody mediates ~~antibody-dependent~~ cellular cytotoxicity.

Claim 6. Cancelled

Claim 7. (Currently Amended) The method of claim 1 wherein said antibody is a humanized antibody produced from the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as accession number PTA-5643.

Claim 8. (Currently Amended) The method of claim 1 wherein said antibody is a ~~chimerized~~ chimeric antibody produced from the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as accession number PTA-5643.

Claim 9. (Withdrawn) An isolated monoclonal antibody or antigen binding fragments thereof encoded by the clone deposited with the ATCC as PTA-5643.

Claim 10. (Withdrawn) The isolated antibody or antigen binding fragments of claim 9, wherein said isolated antibody or antigen binding fragments thereof is humanized.

Claim 11. (Withdrawn) The isolated antibody or antigen binding fragments of claim 9 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells.

Claim 12. (Withdrawn) The isolated antibody or antigen binding fragments of claim 9, wherein said isolated antibody or antigen binding fragments thereof is a chimerized antibody.

Claim 13. (Withdrawn) The isolated antibody or antigen binding fragments of claim 9, wherein said isolated antibody or antigen binding fragments thereof is a murine antibody.

Claim 14. (Cancelled).

Claim 15. (Cancelled).

Claim 16. (Cancelled).